Journal of International Oncology››2016,Vol. 43››Issue (3): 177-179.doi:10.3760/cma.j.issn.1673-422X.2016.03.004
Previous ArticlesNext Articles
Chen Li, Wang Buhai, Dai Erxun, Ge Yizhi, Jiang Yaqi.
Online:
2016-03-08Published:
2016-02-03Contact:
Jiang Yaqi, Email: jyq0913@sina.com E-mail:jyq0913@sina.comChen Li, Wang Buhai, Dai Erxun, Ge Yizhi, Jiang Yaqi.. Concurrent chemoradiotherapy for 90 patients in different parts of esophageal carcinoma[J]. Journal of International Oncology, 2016, 43(3): 177-179.
[1] Aoki T, Nakamura T, Kakeji Y. Current status and future prospects of chemoradiotherapy for esophageal cancer[J]. Gan To Kagaku Ryoho, 2015, 42(10): 1148-1151. [2] Tu L, Sun L, Xu Y, et al. Paclitaxel and cisplatin combined with intensity-modulated radiotherapy for upper esophageal carcinoma[J]. Radiat Oncol, 2013, 8: 75. DOI: 10.1186/1748-717X-8-75. [3] 王澜, 孔洁, 韩春, 等. 781例不同部位食管癌三维放疗预后分析[J]. 中华放射肿瘤学杂志, 2013, 22(1): 18-21. DOI: 10.3760/cma.j.issn.1004-4221.2013.01.006. [4] 王玉祥, 祝淑钗, 李娟, 等. 209例食管癌三维适形放疗疗效分析[J]. 中华放射肿瘤学杂志, 2010, 19(2): 101-104. DOI: 10.3760/cma.j.issn.1004-4221.2010.02.004. [5] 沈文斌, 祝淑钗, 李娟, 等. 93例可手术切除食管癌三维适形放疗长期生存分析[J]. 中华放射肿瘤学杂志, 2011, 20(1): 32-35. DOI: 10.3760/cma.j.issn.10044221.2011.01.012. [6] Al-Halabi H, Paetzold P, Sharp GC, et al. A contralateral esophagus-sparing technique to limit severe esophagitis associated with concurrent high-dose radiation and chemotherapy in patients with thoracic malignancies[J]. Int J Radiat Oncol Biol Phys, 2015, 92(4): 803-810. DOI: 10.1016/j.ijrobp.2015.03.018. [7] Zhu WG, Zhou K, Yu CH, et al. Efficacy analysis of simplified intensity-modulated radiotherapy with high or conventional dose and concurrent chemotherapy for patients with neck and upper thoracic esophageal carcinoma[J]. Asian Pac J Cancer Prev, 2012, 13(3): 803-807. [8] Wood MD, Zaki BI, Gordon SR, et al. Trimodality therapy for stage Ⅱ-Ⅲ carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy[J]. J Thorac Oncol, 2013, 8(4): 487-494. DOI: 10.1097/JTO.0b013e3182829bf3. [9] Francis DO, Hall E, Dang JH, et al. Outcomes of serial dilation for high-grade radiation-related esophageal strictures in head and neck cancer patients[J]. Laryngoscope, 2015, 125(4): 856-862. DOI: 10.1002/lary.24987. [10] Challand T, Thureau S, Dubray B, et al. Esophageal toxicity of radiation therapy: clinical risk factors and management[J]. Cancer Radiother, 2012, 16(5/6): 364371. DOI: 10.1016/j.canrad.2012.07.180. [11] Prisman E, Miles BA, Genden EM. Prevention and management of treatment-induced pharyngo-oesophageal stricture[J]. Lancet Oncol, 2013, 14(9): e380-386. DOI: 10.1016/S1470-2045(13)70160-8. [12] 李保奇. 食管癌放疗后食管狭窄的相关因素研究[J]. 中国医学工程, 2013, 21(7): 62-63. |
[1] | Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma: a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[4] | Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266. |
[5] | Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273. |
[6] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[7] | Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction[J]. Journal of International Oncology, 2024, 51(4): 193-197. |
[8] | Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209. |
[9] | Yao Yixin, Shen Yulin.Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE[J]. Journal of International Oncology, 2024, 51(4): 217-222. |
[10] | Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150. |
[11] | Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156. |
[12] | Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174. |
[13] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[14] | Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185. |
[15] | Yue Hongyun, Zhang Baihong.Differentiation therapies in human cancers[J]. Journal of International Oncology, 2024, 51(2): 109-113. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||